NCT05561751
Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 19, 2026 Show 5 more changesShow less
- Eligibility criteria expanded, about 37 words
- Primary endpoint revised
- Enrollment target: 30 to 28
- Publications: details revised at 1 of 1 entry
- Study description expanded, about 2 words
- Minor Trial status: Active, Not Recruiting to Completed
- Enrollment target: estimated 40 to confirmed 30
- Primary completion date changed from estimate of Aug 31, 2025 to Sep 30, 2025
- Study completion date changed from estimate of Sep 30, 2025 to Oct 31, 2025
- Minor Trial status: Recruiting to Active, Not Recruiting
- Primary completion date: Mar 29, 2025 to Aug 31, 2025
- Study completion date: Jun 30, 2025 to Sep 30, 2025
- Site details revised at 10 of 10 sites
- Notable Primary endpoint revisedv7
- Minor Site contacts updated at 3 of 10 sitesv6
Show 4 earlier versionsHide 4 earlier versions
- Notable Primary completion date: Mar 29, 2024 to Mar 29, 2025
- Study sites: 8 to 10
- Study completion date: Jun 30, 2024 to Jun 30, 2025
- Minor Study sites: 1 to 8v4
- Minor Study description expanded, about 25 wordsv3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Eligibility criteria expanded, about 114 words
- Start date changed from estimate of Nov 30, 2022 to Feb 13, 2023
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Proportion of Participants That Achieve >=2 x 10^6 CD34+ Cells/kg in 2 Leukapheresis Sessions
Timeframe: First two leukapheresis sessions (study days 7 and 8)
Arms and interventions
GPC-100 in combination with propranolol;Experimental
Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arm: • GPC-100 in combination with propranolol; or
GPC-100 in combination with propranolol and G-CSFExperimental
Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arm: • GPC-100 in combination with propranolol and G-CSF.
Drugs: GPC-100, Propranolol, G-CSF
Sites
10 sites in 1 country